Results from pooled analyses of survival data from four studies ( CheckMate -017, -057, -063 and -003; n=664 ) in patients with previously-treated advanced non-small cell lung cancer ( NSCLC ) who were treated with Nivolumab ( Opdivo ) were announced.

In the pooled analysis of the four studies, 14% of all Nivolumab-treated patients were alive at four years.
Notably, in patients with PD-L1 greater than or equal to 1% and less than 1%, four-year overall survival ( OS ) rates were 19% and 11%, respectively.

In the pooled analysis of the two phase 3 trials, CheckMate -017 and -057, the four-year OS rate for Nivolumab-treated patients was 14% compared to 5% for Docetaxel-treated patients.

Additionally, exploratory landmark analysis of OS found that of patients who had a complete or partial response at six months, 58% of those treated with Nivolumab were alive four years later versus 12% of patients treated with Docetaxel.

Of patients who had stable disease at six months, 19% of those treated with Nivolumab were alive four years later versus 2% of patients treated with Docetaxel.

Long-term safety data for Nivolumab from all four studies were consistent with the known adverse event profile and did not reveal any new safety signals.
The most common treatment-related adverse effect was fatigue ( 21.7% ).
The discontinuation rate due to treatment-related adverse events was 8.7% in patients treated with Nivolumab.

These analyses in a large population of patients with previously-treated advanced non-small cell lung cancer have shown, for the first time, that response to Nivolumab correlates to a survival benefit over many years.
These long-term survival outcomes are particularly interesting given that, historically, the average five-year survival rate for this patient population is approximately 5%.

Lung cancer is the leading cause of cancer deaths globally. The two main types of lung cancer are non-small cell and small cell.
Non-small cell lung cancer ( NSCLC ) is one of the most common types of lung cancer and accounts for up to 85% of diagnoses. Survival rates vary depending on the stage and type of the cancer when diagnosed. For patients diagnosed with metastatic lung cancer, the five-year survival rate is approximately 5%. ( Xagena )

Source: BMS, 2019

XagenaMedicine2019